Towards gene therapy of sickle cell disease

E. E. Bouhassira, A. S. Acharya

Research output: Contribution to journalReview articlepeer-review


Sickle cell disease (SCD) is a significant health problem in the United States, in part of Europe and in many developing countries. Progress has been made in the management of the disease but a cure is still elusive except in the rare cases where bone marrow transplant is a practical option. Hopes for a complete universal cure rest mostly on two gene therapy approaches: correcting the mutation that causes the disease, or adding a corrective gene to the genome of the patient. The former approach is extremely attractive but is in its early stages of development. One of the most important remaining obstacles for the latter approach is the control of expression of a transgene integrated at ectopic chromosomal sites. Animal models for SCD should help in the development of the gene therapy methods discussed above, as well as the pharmacological approaches that aim at ameliorating or eliminating the symptoms of SCD.

Original languageEnglish (US)
Pages (from-to)1081-1093
Number of pages13
JournalExpert Opinion on Therapeutic Patents
Issue number7
StatePublished - 2000


  • Anti-sickling globins
  • Cre recombinase
  • Gene therapy
  • Insulator
  • Recombinase-mediated cassette exchange
  • Sickle cell disease

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Towards gene therapy of sickle cell disease'. Together they form a unique fingerprint.

Cite this